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BACKGROUND: Bevacizumab has been used in NSCLC in Europe since its regula-
tory approval in 2007. Bevacizumab has demonstrated significantly improved sur-
vival in randomized phase III trials. The real life outcomes have so far, however,
been assessed only in the US with evidence from routine clinical practice not
previously available in Europe. OBJECTIVES: To investigate Time to Progression
(TTP) in two pilot countries and thus assess the feasibility of such studies in awider
European setting. The primary comparison was bevacizumab-based therapy ver-
sus non-bevacizumab-based therapy in first-line non-squamous NSCLC.
METHODS:Datawere drawn from the Adelphi NSCLCDisease Specific Programme,
a large cross-sectional study of consecutively presenting patients in France and
Germany in 2010. Physicians provided retrospective information regarding disease
status and treatment patterns. TTP was defined as time from start of treatment to
physician-reported disease progression or two weeks before the start of second-
line therapy. A log rank test was applied to test for differences between the two
comparison groups. Cox Proportional Hazard Models were fitted to the data. Sen-
sitivity analyses were run to analyse if age was a prognostic factor for treatment
benefit between the two groups. RESULTS: A total of 895 non-squamous patients
were included in the analyses, of whom 421 had experienced disease progression.
The median time to progression for bevacizumab-treated patients was 8.5 months
compared with 6 months in the comparison group (p0.001). The Hazard ratio
relating to the treatment effect (bevacizumab-based versus non-bevacizumab
based) was 0.65 (95% CI 0.52 to 0.81). The differences in TTP remain significant
between the two first-line therapy groups even after controlling for age.
CONCLUSIONS: The feasibility of using real life oncology studies in Europe to dem-
onstrate extended TTP for bevacizumab-based versus non-bevacizumab therapy
was shown and was consistent with findings of two phase III trials and real life
outcomes from a US study.
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OBJECTIVES: The objective of this study, as part of the Center for Comparative
Effectiveness Research in Cancer Genomics (CANCERGEN), was to establish and
evaluate a process for incorporating formal value of research (VOR) analyses into a
stakeholder-informed research prioritization process for genomic applications for
study in a prospective, randomized comparative effectiveness trial within the
SWOG clinical trials cooperative. METHODS: Six candidate genomic applications,
identified through a landscape-analysis, were prioritized by 13 stakeholders based
on 9 criteria: population impact, adequacy of standard care, analytic and clinical
validity, benefits, harms, economic impact, evidence of need, clinical trial feasibil-
ity, and market factors. We developed decision-analytic based models for the top
three candidates, performed expected value of perfect information calculations,
and presented the results to stakeholders. We evaluated the impact of the VOR
analyses on the test ranking and stakeholder perceptions about the usefulness of
VOR using an online survey. RESULTS: The top three genomic applications based
on the initial rankings were: 1) ERCC1 testing in early stage non-small cell lung
cancer (NSCLC), 2) EGFRmutation testing in advanced NSCLC, and 3) tumormarker
testing to detect recurrence in early stage breast cancer (BC). The VOR was esti-
mated to be: $2.2 to $2.8 billion, $33 million, and $2.1 billion, respectively. After
presentation of the results, the stakeholders changed their ranking to 1) ERCC1, 2)
BC markers, and 3) EGFR. The majority of stakeholders found the VOR information
to be useful (69%), with 53% changing their ranking after consideration of the VOR
findings. In addition, all stakeholders indicated that they would use VOR analyses
in future research prioritization processes. CONCLUSIONS: Stakeholder-informed
research prioritization of genomic applications is a function of many evidence
domains. Our study suggests that with adequate resources, VOR analyses can be
incorporated into this process and provide useful information for research priori-
tization.
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OBJECTIVES: To assess the value of additional research for testing carcinoem-
broynic antigen (CEA), cancer antigen (CA)15-3 and CA 27.29 biomarkers for earlier
detection and treatment of recurrent breast cancer. METHODS: We developed a
decision-analytic model to estimate the expected value of perfect information
(EVPI) and expected value of sample information (EVSI) for a treatment strategy
involving biomarker testing every 3-6 months for the five years following comple-
tion of primary therapy (in addition to standard care), versus standard care alone.
Model parameters and uncertainty ranges were derived from published literature
and expert opinion. EVPI and EVSI were assessed at various willingness-to-pay
thresholds. The affected populationwas estimated frompublished recurrence data
over a discounted 10-year time horizon. RESULTS: At a willingness-to-pay of
$150,000 per quality-adjusted life year, the biomarker strategy and standard-care
strategy resulted in average net-benefits of $598,000 and $600,000, respectively.
The standard care strategy produced greater net-benefit in 57% of simulations.
Among the 43% of simulations where standard care produced greater net-benefit,
the average difference was $11,200. With an affected population of approximately
417,000 patients, the EVPI was $2.1 billion. Preliminary EVSI estimates range from
$36 to $76 million at sample sizes between 500 to 5,000 patients per arm,
respectively. CONCLUSIONS: Our findings indicate that research assessing the use
of breast cancer recurrence biomarkers and consequent earlier treatment could be
highly valuable. The EVPI of approximately $2.1 billion represents the upper bound
of the value of additional research, and is driven by the affected population, testing
sensitivity and specificity, costs, and uncertainty in the choice of optimal strategy.
We are currently conducting EVSI analyses for various trial designs, compared to
the cost of conducting these trials. Our analysis allows decision makers to quanti-
tatively assess and prioritize research efforts in biomarker testing for breast cancer
recurrence relative to alternative research investments.
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OBJECTIVES: Prostate cancer treatments are comparable in long-term outcome;
but associated with different health-related-quality-of-life (HRQOL) outcomes, in-
cluding erectile dysfunction(ED). We studied influence of changes in sexual func-
tion(SF) and bother(SB) on 3-monthly-ED cost over 13.5 years and estimated pre-
dictors of ED costs across and within treatments. METHODS: Data were from
CaPSURE, a national disease registry of 3,276 men with prostate cancer from 31
urology practices completing questionnaires including risk, healthcare utilization
and HRQOL. SF and SB scores(0-100) were measured by UCLA Prostate Cancer In-
dex. ED 2009 costs included drugs, vacuum erection devices and penile implants.
Bootstrapped regression models determined influence of age, BMI, race, marital
status, risk, baseline and changes in SF/SB scores, and co-morbidities on ED costs.
RESULTS: 62% had prostatectomy(RP), 48% were low-risk, and mean age was
64.3(64.1-64.6)years. Baseline SF score was 53.8(52.8-54.8) and SB 62.3(61-63.6).
Mean ED cost was highest for RP ($78.6;$71.1-$86.1), followed by Brachytherapy
($42.7;$30.8-$54.6), Radiation ($35.5;$18-$53) andwatchfulwaiting(WW)($25.5;$8.2-
$42.9). Increasing baseline SF ($0.61,p0.001), SF decline ($30,p0.001), 1co-mor-
bidity ($72,p0.001), treatment type (p0.01), increasing age (p0.07), being mar-
ried ($22,p0.002), and being non-white ($133,p0.001), significantly predicted ED
costs. RP had $42 significantly higher ED cost thanWWwhile Brachy and Radiation
had $15 more. Individuals 70 and older had $32 lower ED costs than 50year olds.
For WW, increasing age ($3,p0.05) and higher BMI ($42,p0.03) significantly pre-
dicted lower ED costs. For RP, higher baseline-SF ($0.66, p0.001), declining-SF
($48,p0.001), improved/no-change SB scores ($15,p0.05), 1co-morbidity
($93,p0.001), married ($34,p0.007), and non-white ($165,p0.001) significantly
predicted higher ED costs. For Brachytherapy, increasing baseline-SF
($0.42,p0.001) and for radiation, higher BMI ($32,p0.06) predicted higher ED
costs. CONCLUSIONS: Treatment type and age were strongest ED cost predictors
with the younger RP patients showing highest ED costs and the older WW group
with lowest ED costs. These results can guide physicians and patients deciding on
prostate cancer therapies.
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OBJECTIVES: To understand factors that impact therapeutic decisions and to un-
derstand healthcare resource utilization. METHODS: A modified Delphi panel
study was conducted, utilizing in-depth interviews with 16 CML-treating physi-
cians to develop key themes and questions for testing, followed by an on-line
survey to capture initial estimates. Results were discussed at a live meeting with 7
CML-treating physicians to develop consensus and complete another round of
surveying. RESULTS: The majority of panelists believe that 20-30% of patients are
not treated in accordance with CML guidelines. An estimated (mean) 25% of pa-
tients are switched from imatinib to nilotinib or dasatinib during the first year.
Community oncologists are more likely to switch treatment due to side effects,
whereas academic clinicians primarily switch for efficacy-related concerns. Six
panelists indicatedmajormolecular response (MMR) is a superior endpoint to com-
plete cytogenetic response (CCyR) with credible evidence to support that MMR
provides superior protection from progression. Panelists believe that molecular
monitoring is less intensive and less time-consuming and is a better predictor of
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progression-free survival. Timing of molecular testing via polymerase chain reac-
tion (PCR) varies. Once patients have achieved and maintained MMR 12 months,
3 panelists would reduce the frequency of cytogenetic testing and 3 would cease
cytogenetic testing. Mutational analysis is not routinely conducted in responding
patients; however, when performed in the second- and third-line settings, muta-
tional analyses are generally conducted once or twice yearly. Healthcare resource
utilization was higher in patients with advanced-phase disease and was 2-3 times
higher in nonresponders than responders. CONCLUSIONS: CML treatment and
monitoring practices may not align with guidelines; furthermore, patient manage-
mentmay differ markedly between treatment settings. Monitoring disease burden
using PCR is expected to become increasingly important with standardization, and
new therapies are anticipated to yield deeper responses.
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BACKGROUND: Erlotinib is an EGFR TKI inhibitor used as monotherapy in second-
line NSCLC patients. Clinical studies have demonstrated the survival benefits of
erlotinib, however outcomes from routine clinical practice have not previously
been assessed in Europe. OBJECTIVES: To investigate Time to Progression (TTP)
and thus to assess the feasibility of such studies in a European setting. The primary
comparison was erlotinib versus chemotherapy in second-line NSCLC.METHODS:
Data were drawn from the Adelphi NSCLC Disease Specific Programme, a large
cross-sectional study of consecutively presenting patients in France and Germany
in 2010. Physicians provided retrospective information regarding disease status
and treatment patterns. TTP was defined as time from start of second-line treat-
ment to physician-reported disease progression or two weeks before the start of
third-line therapy. A log rank test was applied to test for differences between the
two comparison groups. Sensitivity analyses on the treatment effect were run on
EGFRmutationwild-type and non-tested patients. RESULTS: 521 patients receiving
second line therapy were included in the analyses, of which 123 were receiving
erlotinib and 398 were receiving other chemotherapy regimens. 60 patients were
EGFR mutated, 150 were EGFR wild type and 311 were not tested. Only 19 erlotinib
and 83 non-erlotinib patients had progressed. The median time to progression for
erlotinib patients was 17 months compared with 9.5 months in the comparison
group. The Hazard ratio relating to the treatment effect (erlotinib versus non-
erlotinib)was 0.63 (95%CI 0.38 to 1.05) p0.07. The results of the sensitivity analysis
on the EGFRmutation wild-type and non-tested patients resulted in a Hazard ratio
of 0.65, p0.13. CONCLUSIONS: The feasibility of using real life oncology data has
been demonstrated. TTP observed for erlotinib and chemotherapy was similar,
independent of mutation status, in second-line NSCLC.
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OBJECTIVES:Docetaxel (D) prednisone (P), mitoxantrone (MTX), estramustine (E)
and sipuleucel-T (S) are authorized in the US for castrate-resistant prostate cancer
(CRPC) treatment. New agents such as abiraterone and zibotentan are being inves-
tigated. This systematic review aims to assess current clinical evidence of treating
metastatic CRPC (mCRPC). METHODS: MEDLINE, Embase, and Cochrane were
searched to March 22, 2010, as were abstracts from ASCO, ASCO GU, AUA, ESMO,
and EAU (2006 – March 2010). RCTs and observational studies (English) were in-
cluded. Endpoints extracted include overall survival (OS), progression-free survival
(PFS), prostate-specific antigen (PSA) response, and adverse events (AEs). RESULTS:
A total of 171 studies (331 publications) were included: prechemotherapy patients
(71 RCTs, 15 observational), postchemotherapy patients (6 RCTs, 71 observational),
and mixed populations (8 RCTs). D, P, and E were most commonly investigated. In
postchemotherapy RCTs, D P custirsen (14.7 mos) and cabazitaxel P (15mos)
exhibited a relatively high OS compared to other regimens. Regimens with D and
MTX showed longer PFS versus other regimens. D regimens were associated with a
high PSA response (40%). In postchemotherapy observational studies, D  bevaci-
zumab showed a relatively high OS (17.5 mos) and PFS (8.9 mos). In prechemo-
therapy RCTs, S (26 mos) and D  P (27 mos) showed a high OS. D  P showed a
favorable PFS (11mos), as did E etoposide (15mos). Overall, PRO, bone pain, and
skeletal-related events were rarely reported in these studies. Nausea, anemia,
diarrhea, neutropenia, and thrombocytopenia were common across trials.
Grade 3/4 AEs were frequently reported with D-based regimens. CONCLUSIONS:
mCRPC remains a clinical challenge. D was frequently investigated. D improved
survival but produced significant AEs. New treatments for D-refractory patients
are needed.
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OBJECTIVES: To assess the coverage of HPV immunizations two years since their
introduction, and to determine factors associated with vaccination. METHODS:
The present research has been conducted in Maccabi Healthcare Services, the sec-
ond largest HMO in Israel. The study population consisted of women aged 8 to 43.
Multivariate analyses were used to determine independent association of various
factorswith vaccination. RESULTS:The study population included 482,748women,
of which 3.8% purchased at least one HPV vaccine dose. HPV vaccine initiation was
strongly associated with socioeconomic level, with chances for immunization be-
ing approximately 35-fold higher in the highest SES index as compared to the
lowest. High proportion of women aged 21-25 were vaccinated, but the rate in
younger girls, who are the target population were much lower. CONCLUSIONS:
HPV immunizations, which are not part of the current Israeli immunization pro-
gram, are purchased mainly by women older than 20 years from high socio-eco-
nomic classes.
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OBJECTIVES: To determine the trends in type of chemotherapy regimens admin-
istered to early stage or metastatic breast cancer patients in daily practice, as this
information is lacking in published literature.METHODS: Newly diagnosed breast
cancer patients in the period 2000-2008 who received chemotherapy were selected
from the Dutch ECR-PHARMO cohort. The ECR (Eindhoven Cancer registry) records
data on all newly diagnosed cancer patients in the Southeastern Netherlands
whereas the PHARMO RLS (PHARMO Record Linkage System) includes data on,
among other things, in- and outpatient drug use. Chemotherapy regimens were
classified based on the received combinations and sequences. Trends in the distri-
bution of adjuvant chemotherapy regimens (for early stage breast cancer) and
palliative chemotherapy regimens (for metastatic breast cancer) were determined
and stratified by Her2/neu status when possible. RESULTS: In this study, 422 pa-
tients diagnosed with early stage breast cancer received adjuvant chemotherapy.
The use of CMF decreased from 90% in 2000 to almost none since 2005. Adminis-
tration of anthracyclines (without taxanes) increased from 4% in 2000 to 94% in
2005, but lowered to 60% in 2008, being replaced by both trastuzumab and taxanes
(with or without anthracyclines). Among the 82 breast cancer patients who re-
ceived palliative chemotherapy at diagnosis or after breast cancer recurrence, the
use of CMF and anthracyclines (without taxanes) decreased (0% and 15% in 2008,
respectively), while the use of taxanes (with or without anthracyclines) increased
(26% in 2008). Trastuzumab was used as palliative chemotherapy from 2003 on-
wards, with 22% of the metastatic breast cancer patients receiving trastuzumab
containing regimens in 2008, and bevacizumab was administered since 2007 with
19% of the patients receiving bevacizumab containing regimens in 2008.
CONCLUSIONS: Key findings on chemotherapeutic treatment for breast cancer
patients from large clinical trials have been incorporated in the Dutch guidelines
resulting in major changes in patient care.
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OBJECTIVES: There is an increase in incidence ofmalignantmelanoma (MM). How-
ever, there is no systematic estimation of prevalence of advanced MM in the US.
The SEER registry does not provide prevalence by tumor stage or data on tumor
recurrence rates. This study takes a public health approach in reporting MM prev-
alence rate and future trend by tumor stage and age. The objective of this study is
to build upon SEER data to inform public health interventions. METHODS: An ex-
cel-based,multi-cohort natural historymodelwas developed. It employed age- and
stage-specific incidence, recurrence, and all-causemortality rates, and the US Cen-
sus data from up-to-date SEER data and literature. The estimations were projected
to 2015. RESULTS: Our model estimated that there were approximately 1.2 million
MM cases (376 per 100,000 people) in the US in 2010. Of which, (24.4%) were in
advanced stages (regional: 169,975 (14.6%); distant: 114,666 (9.8%)). The estimated
prevalence rate of advanced MM in 2010 was 92 per 100,000 people. Among these
advanced cases, 149,148 cases (52.4%) were in the elderly ( 65y). The total cases of
MM of all stages and advanced cases were projected to increase from 2010 to 2015
by 38.4% and 57.9%, respectively. When compared to the latest SEER reported na-
tionalMMprevalence of all stages in 2007 (793,283 cases), our estimate for the same
year was 965,933 cases, or 21.8% higher, due to difference in projection methodol-
ogy. Of these 2007 MM cases, 332,149 (41.9%) and 429,479 (44.5%) were estimated to
be in the elderly. CONCLUSIONS: Prevalence of advanced MM is projected to in-
crease in the next five years. These estimates help enhance public health aware-
ness. An accurate estimation of disease burden is essential in prioritizing health
care resource allocation and in identifying unmet needs fromdisease prevention to
treatment.
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